Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
ARDELYX, INC. Chief Commercial Officer Eric Duane Foster reported sales of 7,998 shares of common stock on May 21, 2026 at a price of $6.2675 per share.
According to the footnote, these trades were an automatic sell-to-cover tied to vested restricted stock units and were executed solely to cover applicable withholding taxes rather than as discretionary open-market sales.
ARDELYX, INC. Chief Business Officer Mike Kelliher reported selling a total of 7,248 shares of common stock on May 21, 2026 at a price of $6.2675 per share in three separate transactions. A footnote explains these sales were an automatic sell-to-cover triggered by the vesting of restricted stock units, with shares sold solely to cover applicable withholding taxes. This indicates the activity was a tax-related mechanism tied to equity compensation rather than a discretionary reduction of his investment in the company.
Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported multiple open-market sales totaling 6,989 shares of common stock at $6.2675 per share. According to the footnote, these transactions were automatic sell-to-cover trades tied to RSU vesting, executed solely to pay withholding taxes. Williams continued to hold 429,093 shares directly after the transactions.
ARDELYX, INC. President & CEO Michael Raab reported routine sales of company common stock tied to restricted stock unit (RSU) vesting. On May 21, 2026, entities associated with him sold a total of 54,748 shares of Ardelyx common stock at $6.2675 per share.
According to the disclosure, these transactions were an automatic sell-to-cover required by the original RSU grant terms, and the shares were sold solely to cover applicable withholding taxes at vesting. After these sales, Raab directly held about 1,759,848 common shares, with additional indirect holdings of 1,000 shares and 24,364 shares held in family-related trusts.
ARDX submitted a Rule 144 notice relating to Common Stock tied to the vesting of 24,986 restricted stock units on 05/19/2026. The filing also lists three dispositions by Mike Kelliher on 02/20/2026 of 8,434, 1,159 and 2 shares with reported proceeds of $49,465.41, $6,622.29 and $11.41, respectively.
ARDX Form 144 filing records vesting-related sale activity. 5,355 restricted stock units vested on 05/19/2026 and are listed as securities to be sold. The filing also shows prior dispositions on 02/20/2026 of 1,786 shares for $10,474.89 and 247 shares for $1,411.31.
James Parker Brady submitted a Form 144 notice relating to Common Stock of ARDX. The filing lists 6,216 shares to be sold on 05/19/2026 in connection with the vesting of restricted stock units for services rendered. The filing also discloses sales during the past three months: 2,234 shares sold on 02/20/2026 for $13,102.41 and 309 shares sold on 02/20/2026 for $1,765.56.
ARDX filed a Form 144 reporting a proposed sale of Common Stock and vesting of restricted stock units. The filing lists 28,415 shares tied to vesting on 05/19/2026. It also discloses recent dispositions by Eric Duane Foster on 02/20/2026, including 9,176 and 1,261 shares.
ARDX related reporting person Joseph James Reilly reports the vesting of 10,388 restricted stock units on 05/19/2026 and discloses prior open-market sales of common stock on 02/20/2026 totaling 4,991 shares (4,387 + 602 + 2). The filing lists the issuer as the recipient of vested units for services rendered.
Michael Raab reported multiple dispositions of Common Stock under Rule 144. The filings list sales on 02/20/2026, 02/24/2026, 03/16/2026, and 04/15/2026 with per‑trade share counts and proceeds shown. The excerpt also shows vesting of 108,840 restricted stock units on 05/19/2026.